MyFinsight
Home
Blog
About
Contact
Download
Download image
Issuance of common stock
from december 2025...
-$656,230K
Issuance of common stock
and accompanying...
-$272,671K
Proceeds from stock
option exercises
$61,621K
Proceeds from employee
stock purchase plan
$1,685K
Net cash provided by
financing activities
$990,713K
Canceled cashflow
$1,494K
Net increase
(decrease) in cash, cash...
$236,761K
Canceled cashflow
$753,952K
Payments on financing
leases
$1,494K
Maturities of marketable
securities
$488,016K
Stock-based compensation
expense
$59,904K
Deferred revenue
$20,789K
Depreciation and
amortization
$8,313K
Accrued expenses and
other current...
$7,387K
Impairment of long-lived
assets
$3,856K
Operating lease
right-of-use assets
-$2,666K
Contract asset
-$947K
Other non-current
liabilities
$18K
Net cash provided by
(used in) investing...
-$521,061K
Net cash used in
operating activities
-$232,891K
Canceled cashflow
$488,016K
Canceled cashflow
$103,880K
Purchase of marketable
securities
$1,007,628K
Net loss
-$311,351K
Purchase of property and
equipment, net
$1,449K
Premiums and discounts on
available for sale...
-$8,879K
Other non-current
assets
$7,164K
Operating lease
liabilities
-$5,042K
Prepaid expenses and
other assets
$2,361K
Accounts payable
-$1,974K
Back
Back
Cash Flow
source: myfinsight.com
Kymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc. (KYMR)